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EXPERIMENTAL STUDIES
Oral Tolerance With Heat Shock Protein 65
Attenuates Mycobacterium Tuberculosis-Induced
and High-Fat-Diet-Driven Atherosclerotic Lesions
Dror Harats, MD,*† Niva Yacov, BSC,† Boris Gilburd, PHD,‡ Yehuda Shoenfeld, MD,‡
Jacob George, MD§
Tel Hashomer, Or-Yehuda, and Tel Aviv, Israel
OBJECTIVES The goal of this study was to explore the efficacy of oral tolerance with heat shock protein
(HSP) 65 in two apparently non-overlapping models of murine atherosclerosis.
BACKGROUND Atherosclerosis is considered to be a chronic inflammatory process. Autoimmune mechanisms
have been shown to influence atherogenesis in experimental animal models. Heat shock
protein 65 is a candidate antigen thought to drive a proatherogenic immune-mediated
response. Mucosal tolerance is a therapeutic means of accomplishing immune unresponsive-
ness toward a given antigen by feeding it before active induction of the disorder.
METHODS Low-density lipoprotein receptor deficient mice were fed with different doses of HSP65 every
other day for 10 days. Feeding with either bovine serum albumin (BSA) or phosphate buffered
saline (PBS) served as control. One day after the last feeding, mice were challenged either by
immunization with heat killed Mycobacterium tuberculosis or by a high fat diet.
RESULTS Lymphocyte reactivity from mice fed with HSP65 and immunized either against HSP65 or
M. tuberculosis was significantly reduced in comparison with BSA-fed mice. Moreover,
co-incubation of splenocytes—from mice with tolerance induced with HSP65 but not
BSA—with HSP65-reactive lymphocytes resulted in the suppression of HSP65 reactivity by
the latter cells. Interleukin-4 production by HSP65-fed and immunized mice was increased
upon priming with respective protein. Early atherosclerosis was attenuated in HSP65-fed
mice, compared with either BSA- or PBS-fed mice, regardless of the method employed to
induce fatty streaks (M. tuberculosis immunization or high-fat diet).
CONCLUSIONS Oral tolerance induced with HSP65 could prove to be a novel means of suppressing
atherogenesis. (J Am Coll Cardiol 2002;40:1333–8) © 2002 by the American College of
Cardiology Foundation
The relatively modern view of atherosclerosis is of a chronic
inflammatory process, wherein cellular and humoral com-
ponents act to bring about gradual vessel obstruction (1,2).
Recently, this concept has been further extended by the
detection of antigen-driven immune responses toward var-
ious plaque antigens. Accordingly, modified forms of low-
density lipoprotein (LDL), heat shock proteins (HSP), and
phospholipid binding proteins have been shown to drive
humoral and cellular reactions and, thus, to influence the
progression of atherosclerosis (3).
Heat shock proteins are a family of approximately 25
molecules with highly conserved structures that serve pro-
tective roles (4). However, HSP (i.e., HSP65) has been
implicated as a target autoantigen in several experimental
autoimmune diseases (i.e., arthritis, type I diabetes) (5,6).
There are abundant data to support the involvement of
HSP60/65 in atherogenesis: anti-HSP65 as well as anti-
HSP60 antibodies have been demonstrably associated with
atheromatous lesions in humans (7,8). Studies conducted in
rabbits (9) and mice (10–12) show that the generation of an
HSP65-induced immune response by immunization with
the recombinant protein or with an HSP65-rich preparation
of Mycobacterium tuberculosis enhances atherogenesis.
Mucosal “tolerization” (i.e., the intentional induction of
tolerance by means of chemical or biological agents) is a
method by which a state of unresponsiveness is induced in
the host immune system against a given antigen (13). Because
organ-specific autoimmune diseases have been shown to be
triggered by distinct antigens, tolerization has been employed
in order to block these responses to bring about attenuation of
disease outcome in experimental models.
As autoimmune processes have been shown to participate
in atherosclerosis, with abundant evidence pointing to
HSP65 as a possible antigenic candidate; we therefore
reasoned that tolerization of the immune response to this
antigen would result in reducing atherosclerosis.
METHODS
Mice. Low-density lipoprotein receptor deficient (LDL-
RD) female mice (14), age six weeks, were fed either normal
chow-diet containing 4.5% fat by weight (0.02% choles-
terol) or an atherogenic diet (Western type diet, TD 96125,
From the *Institute of Lipid and Atherosclerosis Research, Sheba Medical Center,
Tel Hashomer, Israel; †Vascular Biogenics Ltd., Or-Yehuda, Israel; ‡The Research
Unit of Autoimmune Diseases, Sheba Medical Center, Sheba, Israel; and §Depart-
ment of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel
Aviv, Israel.
Manuscript received April 25, 2001; revised manuscript received May 30, 2002,
accepted June 27, 2002.
Journal of the American College of Cardiology Vol. 40, No. 7, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)02135-6
Harlan Teklad; 42% of calories from fat, 43% from carbo-
hydrates, 15% from protein).
Cholesterol level determinations. Total plasma choles-
terol levels were determined by using an automated enzy-
matic technique (Boehringer Mannheim, Germany).
Study design. Two experiments were designed in which
atherosclerosis was induced either by a high-fat diet or by
immunization with heat-killed M. tuberculosis (10,12).
In the first experiment, LDL-RD mice were fed by a
nasogastric tube, five doses (every other day) of recombinant
Mycobacterial HSP65 in phosphate buffered saline (PBS) in
three different concentrations (50 g/dose, 5 g/dose, and
0.5 g/dose). Control mice were either fed a control antigen
(bovine serum albumin [BSA] 50 g) or not fed. One day
after the last feeding, all mice were challenged by an
immunization with heat killed suspension of M. tuberculosis
(10 mg/ml; 100 g/mouse) emulsified in incomplete
Freund’s adjuvant to induce fatty streaks (10). Mice were
euthanized 12 weeks after the last feeding.
In the second experiment, the mice were fed five doses of
HSP65 (100 g, 10 g, 1 g, and 0.1 g/mouse) or BSA
(100 g/mouse) every other day, and the Western diet was
substituted for chow one day after the final feeding. An
additional group that was fed no antigen served as control.
Mice were euthanized five weeks after the initiation of the
high-fat diet.
Proliferation assays. Draining inguinal lymph nodes (tak-
en 8 days after immunization) or splenocytes (taken upon
euthanization) were collected from four HSP65-, M.
tuberculosis-, and PBS-immunized mice for the proliferation
studies. The assays were performed as previously described
(12). Briefly, 1 106 lymph node cells/ml were incubated in
triplicates for 72 h in 0.2 ml of culture medium in microtiter
wells in the presence 10 g/ml HSP65. Proliferation was
measured by the incorporation of [3H] thymidine into
DNA during the final 12 h of incubation. The results were
computed as stimulation index: the ratio of the mean cpm of
the antigen to the mean background cpm obtained in the
absence of the antigen. Standard deviations were always
10% of the mean counts per min.
To test efficacy of tolerance in vitro, splenocytes from
HSP65-tolerized mice were co-cultured with lymph node
cells obtained from mice immunized against HSP65 in the
presence of 10 g/ml of HSP65 for 72 h. The next steps,
including thymidine uptake, were performed similarly to the
similar proliferation assays, as described previously.
Interferon-gamma (IFN-), interleukin-4 (IL-4), and
tumor growth factor-beta (TGF-) secretion by tolerized
lymph node cells. Conditioned medium was obtained
from the lymph node proliferation experiments after 48 h of
culture in the presence of HSP65. IFN-, IL-4, and
TGF- concentrations were determined by enzyme-linked
immunosorbent assay (ELISA) kits according to the man-
ufacturer’s suggestions (R&D Systems).
Figure 1. Oral feeding with heat shock protein (HSP) 65 tolerizes immune
responses to HSP65 in vivo. Low-density lipoprotein receptor deficient
mice were immunized with HSP65 (10 g/mouse) emulsified in incom-
plete Freunds adjuvant in the hind footpad. The mice were fed with either
HSP65 or bovine serum albumin (BSA) before immunization as described
in the Methods section. Lymphocytes obtained from draining inguinal
lymph node cells of mice from both groups were cultured in the presence
of different concentrations of HSP65 (A). Reactivity to HSP65 was
determined by thymidine incorporation by lymphocytes and expressed as
stimulation index. (B) Reactivity to HSP65 was evaluated in a similar
manner in HSP65- or BSA-fed mice immunized with heat-killed prepa-
ration of Mycobacterium tuberculosis. *p  0.01. Hatched bar  BSA-fed;
solid bar  HSP65-fed.
Abbreviations and Acronyms
BSA  bovine serum albumin
ELISA  enzyme-linked immunosorbent assay
HSP  heat shock protein
IFN-  interferon-gamma
IL-4  interleukin-4
LDL-RD  low-density lipoprotein receptor deficient
PBS  phosphate buffered saline
TGF-  tumor growth factor-beta
Th  T helper
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Detection of anti-HSP65 antibodies and of IgG iso-
types. Recombinant HSP65 (1g/ml) in PBS (pH 7.2) was
coated onto flat bottom 96-well ELISA plates (Nunc,
Denmark) by overnight incubation, and the assay was
performed as previously described (12).
IgG isotypes in the sera of HSP65-tolerized and non-
tolerized mice were determined by an ELISA kit (phospha-
tase; Southern Biotechnology Associates, Birmingham, Al-
abama) according to the manufacturer’s suggestions.
Assessment of atherosclerosis and immunohistochemis-
try. The quantification of atherosclerotic fatty streak lesions
was done by calculating the lesion size in the aortic sinus as
previously described (15), with a few modifications. Briefly,
the heart and upper section of the aorta were removed from
the animals, and the peripheral fat cleaned carefully. The
upper section was embedded in OCT medium and frozen.
Every other section (10 m thick) throughout the aortic
sinus (400 m) was taken for analysis. The extent of
atherosclerosis was evaluated at the level of the aortic sinus.
Processing and staining of the tissue with oil-red O was
carried out according to Paigen et al. (15).
Immunohistochemical staining for CD3 cell number was
done on 5 m–thick frozen sections of aortic sinus. Rat
anti-mouse CD3 primary antibodies were used for probing.
Slides were developed with the three amino-9-
ethylcarbonasole substrate. Sections were counterstained
with hematoxylin. Spleen sections were used as a positive
control. Staining in the absence of first or second antibody
was used as a negative control.
Statistical analysis. All parameters were compared em-
ploying a one-way analysis of variance, followed by a
Fisher-protected least significant difference test. P  0.05
was accepted as statistically significant. Results are pre-
sented as mean  SEM.
RESULTS
Oral feeding with different doses of HSP65 or with control
antigen (BSA) did not alter the lipid profile. These results
were consistent in both experiments: levels of total choles-
terol and triglycerides did not differ between groups (data
not shown), and animal weight also did not differ between
groups (data not shown).
The effect of HSP65 tolerization was tested in vivo and in
vitro. Mice fed five doses of HSP65 (50 g)—the concen-
tration found most potent—or control antigen (BSA) were
immunized against HSP65, and proliferation was assessed
using thymidine uptake. We have found that lymphocytes
from HSP65-fed mice exhibited significantly reduced pro-
liferation to HSP65 (52% at 10 g HSP65) compared with
BSA-fed mice (Fig. 1A). Similarly, lymphocytes from
HSP65-fed M. tuberculosis immunized mice were signifi-
cantly less reactive to HSP65 than cells from animals fed
BSA (Fig. 1B). Splenocytes from HSP-tolerized mice were
capable of significantly reducing the reactivity of lymph
node cells from HSP65 to the antigen upon their co-
incubation (Fig. 2).
To evaluate whether regulatory cells were induced by oral
tolerization with HSP65, we assessed cytokine production
by lymph node cells of treated versus non-treated animals.
We have found that lymph node cells from HSP65-
tolerized LDL-RD mice produced significantly (3.8 times)
more IL-4 than non-tolerized cells (p  0.01) (Fig. 3).
IFN- levels in the cultured medium did not differ
between mice that were tolerized (mean of 3,121  438
pg/ml) and mice that were not tolerized (2,904  515
pg/ml) with HSP65 (p  0.77). TGF- levels produced by
Figure 2. In vitro induction of tolerance to heat shock protein (HSP) 65 by
co-culture of tolerized splenocytes with HSP65 responder lymph node
cells. To assess in vitro tolerization, 105 splenocytes from HSP65 or bovine
serum albumin (BSA)-fed (i.e., mice that were fed 5 times with HSP65, 50
g/dose or BSA) were incubated in the presence of 104 lymph node cells
from Mycobacterium tuberculosis immunized mice in the presence of
different concentrations of HSP65. The figure represents average values
obtained from three studies, each repeated twice. *p  0.05. Hatched
bar  BSA-fed splenocytes; solid bar  HSP-fed splenocytes.
Figure 3. Induction of T helper 2 cytokines by orally tolerized mice.
Lymph node cells were obtained from heat shock protein (HSP) 65
tolerized low-density lipoprotein receptor deficient mice immunized with
HSP65 upon priming in vitro with 10 g/ml HSP65 for 48 h.
Interleukin-4 (IL-4) levels in the conditioned medium were assessed by a
capture enzyme-linked immunosorbent assay kit as described in the
Methods section. *p  0.01.
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lymph node cells from tolerized and non-tolerized mice
were below the detection threshold.
To explore the possible effect of the change in cytokine
(Th2 dominance) on the IgG isotype patterns, we have
made solid phase assessment of total IgG isotypes and
HSP65 isotypes. No detectable differences were evident in
the levels of total IgG isotypes between HSP65-tolerized
and non-tolerized cells (Fig. 4A). Additionally, no skewing
of the anti-HSP65 IgG isotype pattern was observed in
HSP65-immunized mice between the tolerized and non-
tolerized groups (Fig. 4B).
In the first experiment, fatty streaks were significantly
reduced in mice fed either 50 g (n  9; mean lesion size
of 8,600 1,600 m2), 5 g (n 8; 22,500 2,950 m2),
or 0.5 g (n 16; 26,700 2,950 m2) HSP65, compared
with BSA (n  6; 49,300  5,400 m2) (p  0.0001, p 
0.001, and p  0.01, respectively) (Fig. 5A).
Because no differences were evident when BSA was
compared with PBS (Fig. 5A and 6), the next experiment
was carried out employing BSA as control. In the second
experiment, when Western diet was employed, lesion size in
BSA-fed mice was 76,900  11,700 m2 (n  10). In
comparison with BSA administration, prior feeding with
HSP65 reduced atherosclerosis when doses of 100 g (n 
13; 30,000  8,000 m2), 10 g (n  13; 34,200  6,900
m2), and 1 g (n  13; 36,300  6,300 m2) (p  0.01
for all) were employed (Fig. 5B and 6). Oral feeding with
0.1 g/dose of HSP65 did not significantly reduce fatty
streaks compared with control.
Oral tolerance did not alter the number of plaque-
infiltrating CD3 lymphocyte positive cells between the
different groups (0 to 4/positive cells/fatty streak; data not
shown). Similarly, no differences were evident with regard
to plaque Mac-1 positive cells between tolerized and non-
tolerized mice.
Figure 4. Oral tolerance with heat shock protein (HSP) 65 does not alter
IgG isotype distribution. Sera was obtained from all mice tolerized with
HSP65 and from non-tolerized mice from experiment 1 and 2. IgG
anti-HSP65 isotypes were assessed in the first experiment (A), whereas
IgG isotypes (total) were probed in the second experiment (B) employing
a capture enzyme-linked immunosorbent assay. Hatched bar  HSP65;
open bar  bovine serum albumin (BSA).
Figure 5. Oral tolerance with heat shock protein (HSP) 65 attenuates
atherogenesis in Mycobacterium tuberculosis and high-fat diet fed low-
density lipoprotein receptor deficient mice (LDL-RD). The LDL-RD
mice were fed with different doses of HSP65. One day after the last
feeding, all mice were immunized with M. tuberculosis and euthanized 12
weeks afterwards. Lesion size was assessed after Oil red O staining of
sections obtained at the level of the aortic sinus (A). *p 0.01; **p 0.001;
***p0.0001. In the second experiment, LDL-RD mice were fed different
concentrations HSP65, bovine serum albumin (BSA), or phosphate buff-
ered saline (PBS) and fed a high fat diet for four weeks until euthanization.
Atherosclerosis was assessed similar to the first experiment (B). *p  0.01.
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DISCUSSION
In the current study, we have shown, for the first time,
application of oral tolerization with HSP65 as a novel
means of suppressing atherosclerosis.
Oral tolerance with HSP65 and suppression of fatty
streak formation. In previous studies, we successfully em-
ployed oral tolerance in a model of fatty streak induction by
immunization with heat killed suspension of M. tuberculosis
(10–12). In the present model, cellular immunity to the
mycobacterial HSP65 is involved in promoting fatty streaks,
similar to the induction of adjuvant arthritis in rats. Thus,
we sought to induce a state of unresponsiveness of the
cellular immune response to HSP65 in order to reduce the
development of atherosclerosis. In the parallel model of
adjuvant arthritis, amelioration of the inflammatory joint
lesions was indeed accomplished by prior feeding with
HSP65 (16). More intriguing, however, are the results
obtained in the second experiment, in which feeding
HSP65 led to suppression of high-fat-diet-induced athero-
sclerosis. In this model of atherosclerosis, spontaneous
reactivity to HSP65 is not evident, as in the M. tuberculosis-
and HSP65-driven fatty-streak model.
Oral feeding of HSP65 and suppression of cellular
immunity to HSP65. Several mechanisms are operable in
oral tolerance and appear to be dependent on antigen dosing
and preparation. It is thought that whereas high-dose
feeding leads to clonal deletion/anergy (17,18), low doses
induce regulatory cells (19,20) capable of altering cytokine
production. We monitored the tolerizing effect of HSP65
feeding by several methods. In vivo, we explored the cellular
reactivity to HSP65 and found it was significantly dimin-
ished in HSP65-fed compared with BSA-fed mice. These
findings were reinforced by in vitro studies showing that
co-incubation of HSP65-tolerized splenocytes with
HSP65-reactive lymphocytes is capable of reducing their
proliferation to the antigen.
We have recently found that antigen-driven cellular
immune responses are capable of transferring atherosclero-
sis, regardless of the lipid profile (21). These results were
supported by transfer experiments employing immunodefi-
cient apoE deficient mice (22). In the model of HSP65-
driven fatty streaks, lymphocyte reactivity appears to play a
proatherogenic role (23). Thus, tolerization to HSP65 can
intuitively explain the reduction in fatty streaks, and our
observations could support the operability of mechanisms
that promote clonal anergy/deletion as responsible for the
reduced fatty streaks.
Oral tolerance with HSP65 and modulation of T-helper
cytokine production. However, as could be observed, there
is no strict correlation between the extent of atherosclerosis
reduction and the suppression of immune responses to
HSP65. Thus, additional mechanisms may be present. We
have chosen to explore the possibility that regulatory cells
are induced, capable of producing Th2 and Th3 cytokines
or, alternatively, downregulating Th1 cytokines upon en-
countering HSP65. We have found that oral feeding of
HSP65 induced the production of lymphocytes capable of
significantly increasing the production of the Th2 cytokine
IL-4. These were not paralleled by a suppressive effect on
Th1 cytokine secretion, as evidenced by the unaltered
IFN- production. These results are consistent with previ-
ous reports implying that both of these Th2 cytokines are
essential for the protection afforded by oral tolerance (24).
The relevance to atherosclerosis can be understood when
considering the observations by Huber et al. (25) showing
that IL-4 plays a protective role in atherosclerosis. The lack
of significant Th1 suppression despite elevated Th2 cyto-
kines in response to HSP65 is also evident by the lack of
change in the total IgG isotype pattern in the serum as well
as in the HSP65-specific IgG isotype distribution in the
immunized mice.
Figure 6. Atherosclerosis in heat shock protein (HSP) 65 and bovine
serum albumin (BSA) tolerized low-density lipoprotein receptor deficient
(LDL-RD) mice. Representative Oil-red O stained section from BSA (A)
and HSP65 (B) and fed LDL-RD mice.
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TGF- represents the most commonly described cyto-
kine associated with favorable oral tolerance (13). Interest-
ingly, TGF- production was, similar to IFN-, not influ-
enced by oral tolerance with HSP65. This observation can
be explained by data showing that TGF- levels are
significantly reduced in atherosclerosis (26). Because the
mice employed for the current study are hyperlipidemic and
atherosclerosis prone, we speculate that this propensity may
have been responsible for the lowering of TGF- to levels
that could not be counterregulated by oral tolerization.
From the above observations, it is apparent that no
conclusive evidence can be obtained as to the exact mech-
anism mediating the tolerizing effect on atherosclerosis.
Moreover, the effect of HSP65 feeding may not be specific,
considering that the protective effect on atherosclerosis is
maintained even when proliferative responses to HSP65 are
not significant. A modulating effect on Th2 cytokine up-
regulation could also be operable and perhaps even domi-
nant. The use of additional antigens considered as candidate
autoantigens in atherosclerosis may provide partial answers
to these questions.
Conclusions. In conclusion, we have found that athero-
sclerosis-prone mice can be tolerized to HSP65, resulting in
suppression of plaque formation. Several mechanisms, in-
cluding clonal anergy and induction of regulatory cells
capable of inducing Th2 cytokine dominance, are probably
involved in the beneficial effect. This means of selectively
modulating the immune system by mucosal tolerance may
prove to be a novel therapeutic strategy in atherosclerosis.
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